Have a personal or library account? Click to login
Epidermal Growth Factor Receptor Mutation Status and the Impact on Clinical Outcomes in Patients with Non-Small Cell Lung Cancer Cover

Epidermal Growth Factor Receptor Mutation Status and the Impact on Clinical Outcomes in Patients with Non-Small Cell Lung Cancer

By: HM Huang,  Y Wei,  JJ Wang,  FY Ran,  Y Wen,  QH Chen and  BF Zhang  
Open Access
|May 2023

Figures & Tables

Figure 1.

Screening and follow-up of patients NSCLC: non-small cell lung cancer; EGFR: epidermal growth factor receptor; PFS: progression-free survival; OS: overall survival
Screening and follow-up of patients NSCLC: non-small cell lung cancer; EGFR: epidermal growth factor receptor; PFS: progression-free survival; OS: overall survival

Figure 2.

The contribution of EGFR mutation types
The contribution of EGFR mutation types

Figure 3.

Kaplan - Meier curve of progression-free survival (A) and overall survival (B) in advanced NSCLC patients with EGFR mutations or wild type EGFR.
Kaplan - Meier curve of progression-free survival (A) and overall survival (B) in advanced NSCLC patients with EGFR mutations or wild type EGFR.

Univariate analysis and multivariate logistic regression analysis for EGFR mutations

VariableUnivariate analysis Multivariate analysis
P-value OR95% CIP-value
Gendera<0.001
    Male 1References
    Female 1.350.57-3.190.498
Age0.308
    >65
    ≤65
Smoking statusa<0.001
    Current smoker 1References
    Former smoker 1.320.51-3.410.568
    Never smoker 2.761.04-7.340.042
Histology typesa<0.001
    Non-adenocarcinoma 1References
    Adenocarcinoma 17.072.21-132.040.007
Stage classification0.990
    I-II
    IIIA
    IIIB
    IV

Distribution of exons 18-21

Patient characteristicsEGFR mutations N (%)Exon 18Exon 19Exon 20Exon 21
Gender
    Female62(60.2%)5(83.3%)28(56.0%)1(50.0%)28(60.9%)
    Male41(39.8%)1(16.7%)22(44.0%)1(50.0%)18(39.1%)
Age
    >6542(40.8%)0(0.0%)19(38.0%)2(100.0%)22(47.8%)
    ≤6561(59.2%)6(100.0%)31(62.0%)0(0.0%)24(52.2%)
Smoking status
    Current smoker15(14.9%)1(16.7%)6(12.5%)0(0.0%)8(17.4%)
    Former smoker11(10.9%)0(0.0%)5(10.4%)1(50.0%)6(13.0%)
    Never smoker75(74.3%)5(83.3%)37(77.1%)1(50.0%)32(69.6%)
Histology types
    Adenocarcinoma102(99.0%)6(100.0%)50(100.0%)2(100.0%)45(97.8%)
    Non-adenocarcinoma1(1.0%)0(0.0%)0(0.0%)0(0.0%)1(2.2%)
Stage classification
    I-II32(31.1%)2(33.3%)17(34.0%)0(0.0%)13(28.3%)
    IIIA3(2.9%)0(0.0%)2(4.0%)0(0.0%)1(2.2%)
    IIIB16(15.5%)1(16.7%)8(16.0%)0(0.0%)7(15.2%)
    IV52(50.5%)3(50.0%)23(46.0%)2(100.0%)25(54.3%)

Mutations detected in exons 18-21 of EGFR

ExonEGFR mutation types
Exon 18G719A; G719C; G719S
Exon 19E746_A750del (Cosmic ID:6223); E746_T751>A; E746_S752>V; L747_A750>P; L747_E749del; L747_S752del; E746_A750del(Cosmic ID:6225); L747_A750>P; L747_P753>S; L747_T751del; L747_T751>P
Exon 20T790M; S768I; H773_V774insH; D770_N771insG; V769_D770insASV
Exon 21L858R; L861Q

Patient characteristics

Patient characteristicsTotal N(%)EGFR mutations N (%)Wild type EGFR N (%)P-value
Gender <0.001
    Female108(45.4%)62(57.4%)46(42.6%)
    Male130(54.6%)41(31.5%)89(68.5%)
Age 0.308
    ≥65106(44.5%)42(39.6%)64(60.4%)
    <65132(55.5%)61(46.2%)71(53.8%)
Smoking history <0.001
    Current smoker58(25.6%)15(25.9%)43(74.1%)
    Former smoker37(16.3%)11(29.7%)26(70.3%)
    Never smoker132(58.1%)75(56.8%)57(43.2%)
Histology types <0.001
    Adenocarcinoma211(88.7%)102(48.3%)109(51.7%)
    Non-adenocarcinoma27(11.3%)1(3.7%)26(96.3%)
Stage classification 0.990
    I-II74(31.1%)32(43.2%)42(56.8%)
    IIIA7(2.9%)3(42.9%)4(57.1%)
    IIIB39(16.4%)16(41.0%)23(59.0%)
    IV118(49.6%)52(44.1%)66(55.9%)
Language: English
Page range: 29 - 36
Published on: May 2, 2023
Published by: Macedonian Academy of Sciences and Arts
In partnership with: Paradigm Publishing Services
Publication frequency: 2 issues per year

© 2023 HM Huang, Y Wei, JJ Wang, FY Ran, Y Wen, QH Chen, BF Zhang, published by Macedonian Academy of Sciences and Arts
This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 3.0 License.